Rare Cancers – more common than you think
ESMO 2016: Video Hightlights - Sarcoma
More than 4.3 million people in the European Union are affected by rare cancers. Despite the rarity of each of the 198 rare cancers, they represent in total about 22% of all cancer cases, including all cancers in children, diagnosed in the EU28 each year.
Rare Cancers Europe (RCE) is a multi-stakeholder initiative dedicated to putting rare cancers firmly on the European policy agenda and to implementing 39 political and stakeholder recommendations.
-
Rare Cancers: The Challenges
- Late or incorrect diagnosis
- Lack of access to appropriate therapies and clinical expertise
- Very limited number of clinical studies due to the small number of patients -
Specific clinical trial methodology needed for rare cancers
RCE calls for new criteria to be used in clinical trials on rare cancer treatments. Read the full article.
-
Rare Cancers: Pathologic Diagnosis
Rare Cancers Europe Consensus Statement summary on the urgent actions needed to improve pathologic diagnosis of rare cancers.
Read the Statement
Latest News
-
20 Jun 2017
Immune Cells Deliver Cancer Drugs to the Brain
Neutrophils loaded with the chemotherapy drug paclitaxel traverse the blood-brain barrier and kill residual cancer cells after tumor-resection surgery.
-
01 Jun 2017
Century-Old Tumours Offer Rare Cancer Clues
DNA sequences from 100-year-old tumour samples could bolster childhood cancer research
-
10 May 2017
New nanotechnology application for difficult-to-treat cancers
A new treatment combining shock waves with nanoparticles can successfully treat tumours that are difficult to target using conventional chemotherapy.